Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Cardiology
Latest News
Advertisement
CME Content
Advertisement
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics, discussed the company’s research on capsids, promoters, and manufacturing improvements.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The Senior Director and Head of Technology Development at Epic Bio discussed potential applications of the new technology.
The medical director of clinical development at AskBio discussed the progress of an early clinical trial of AB-1002.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The director of the Mount Sinai Fuster Heart Hospital discussed how artificial intelligence complements data-driven research.
The chief of cardiology at Weill Cornell Medical College discussed the center’s increased focus on genetic research.
The Don and Marilyn Anderson Professor of Oncology at University of Wisconsin – Madison shared highlights from the discussion.
Other of the company’s RNAi therapies have recently shown promising data in hyperlipidemia and asthma.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Current handling guidelines do not align between the laboratory and clinical settings.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
An ASGCT poster focused on special ethical considerations of gene therapy human research and how to address them.
The associate professor of otolaryngology from Harvard Medical School also shared his excitement for the positive data on AAV1-hOTOF.
The cofounder and chief executive officer of Verve Therapeutics discussed the company’s pipeline.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Jonathan W. Weinsaft, MD, chief of cardiology and professor of medicine at Weill Cornell Medical College, discussed research the center is doing in the space.
The chief executive officer of Tenaya Therapeutics discussed the growing interest in genomic medicines in cardiology.
Oncological trials of biologics also face particularly higher rates of clinical holds.
The chief executive officer of Tenaya Therapeutics discussed the company’s decision to supplement the gene transfer programs in its pipeline with gene editing programs.
Omer A. Abdul Hamid, MD, pediatric neurologist at Nemours Children’s Health offered advice and discussed important practical considerations with administering gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
VERVE-102 is intended to reduce LDL-C in patients with heterozygous familial hypercholesterolemia or premature coronary artery disease.
The chief executive officer of Tenaya Therapeutics discussed the company’s research on capsids, promoters, and manufacturing improvements.
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – December 3, 2025
2
Lessons Learned From the Past 25 Years of Cell and Gene Therapy Research
3
FDA Activity Recap: November 2025 Features SMA Approval, Boxed Warning for Elevidys, and More
4
Key Unknowns Remain in Cell and Gene Therapy
5
